On October 20, 2025 Valink Therapeutics Inc. ("Valink"), a private biotechnology company developing next-generation oncology therapeutics with a focus on bispecific antibody-drug conjugates (bsADCs) and complementary modalities for improved patient outcomes, reported the closing of a $11.8 million funding round and the expansion of its U.S. presence, with headquarters in Cambridge, Massachusetts. Proceeds from the financing will be used to advance Valink’s pipeline of first-in-class treatments designed to deliver enhanced efficacy, safety and precision in the treatment of cancer and other diseases.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Valink’s bsADC technology aims to address key limitations of current ADCs by integrating novel targeting strategies with improved payload delivery. The company is also exploring complementary therapeutic modalities to broaden its impact across multiple cancer indications.
The financing was led by European venture capital fund redalpine, with participation from new investors LongeVC and Oxford Science Enterprises. Existing investors, including RV Invest, p53 Invest, and Hoxton Ventures also contributed to the round.
"We are grateful to redalpine and our syndicate of new and existing investors for their confidence in our vision and strategy," said Arne Scheu, DPhil, Co-founder and Chief Executive Officer of Valink Therapeutics. "This financing strengthens our position as a leader in next-generation bispecific ADCs and supports the advancement of our oncology pipeline toward key milestones. Our V-gate approach and proprietary drug discovery engine expand the frontier of antibody drug conjugates, offering the potential for first-in-class medicines to address areas of high unmet need in oncology and beyond."
"At redalpine, we back technologies that reshape paradigms. Valink’s discovery platform and V-gate approach represent a compelling advancement on traditional ADC strategies – unlocking new therapeutic possibilities by fusing programmable biology and a novel framework for target synergy," said Michael Sidler, redalpine founding partner and member of Valink Therapeutics board of directors. "We’re excited to lead this round and support Valink’s mission to address real-world disease biology with precision and adaptability."
(Press release, Valink Therapeutics, OCT 20, 2025, View Source [SID1234656842])